Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze EBS stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate EBS investment potential.

What is EBS stock price today?

Get real-time EBS stock price, historical data, and price charts on Financhill. Track EBS performance with our advanced analysis tools.

Is EBS a good investment?

Evaluate EBS investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy EBS stock?

To buy EBS stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of EBS?

View detailed market capitalization data and company valuation metrics for EBS on our comprehensive analysis page.

What is the P/E ratio of EBS?

Use our fundamental analysis tools to view EBS P/E ratio and compare valuation metrics with industry peers.

What are EBS earnings?

View EBS earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Emergent BioSolutions, Inc. 10K Form

Buy

EBS
Emergent BioSolutions, Inc.

Last Price:

$12.06

Seasonality Move:

3.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02	10Q	EBS/Emergent BioSolutions, Inc. Quarterly
2023-12-11	10Q	EBS/Emergent BioSolutions, Inc. Quarterly
2023-08-09	10Q	EBS/Emergent BioSolutions, Inc. Quarterly
2023-05-10	10Q	EBS/Emergent BioSolutions, Inc. Quarterly
2022-11-09	10Q	EBS/Emergent BioSolutions, Inc. Quarterly
2022-08-02	10Q	EBS/Emergent BioSolutions, Inc. Quarterly

Receive EBS News And Ratings

See the #1 stock for the next 7 days that we like better than EBS

EBS Financial Statistics

Sales & Book Value

Annual Sales:	$1B
Cash Flow:	$-5.7M
Price / Cash Flow:	478.13
Annual Sales:	$11.05
Price / Book:	1.09

Profitability

EPS (TTM):	1.29400
Net Income (TTM):	$75.9M
Gross Margin:	$305.2M
Return on Equity:	14.25%
Return on Assets:	5.29%

Emergent BioSolutions, Inc. Earnings Forecast

Key Emergent BioSolutions, Inc. Financial Ratios

The Gross Profit Margin over the past 23 years for EBS is 29.24%.
The Selling, General & Administrative Expenses for EBS have been equal to 29.51% of Gross Profit Margin.
The Research & Development expenses have been 6.22% of Revenue.
The Net Earning history of EBS is -18.26% of Total Revenues.
Per Share Earnings over the last 24 years have been positive in 13 years.

Emergent BioSolutions, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NYSE
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	EBS
CUSIP:	29089Q
Website:	emergentbiosolutions.com

Debt

Debt-to-Equity Ratio:	1.15
Current Ratio:	5.76
Quick Ratio:	2.93

Price-to-Earnings

Trailing P/E Ratio:	0
Forward P/E Ratio:	3.58

EBS Technical Analysis vs Fundamental Analysis

Buy

Emergent BioSolutions, Inc. (EBS) is a Buy

Is Emergent BioSolutions, Inc. a Buy or a Sell?

Emergent BioSolutions, Inc. stock is rated a Buy

The current Emergent BioSolutions, Inc. [EBS] share price is $12.05. The Score for EBS is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.